Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism

Methods Enzymol. 1996:272:210-8. doi: 10.1016/s0076-6879(96)72025-6.

Authors

J A Goldstein¹, J Blaisdell

Affiliation

¹ Laboratory of Biochemical Risk Analysis, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.

PMID: 8791779
DOI: 10.1016/s0076-6879(96)72025-6

No abstract available

MeSH terms

Anticonvulsants / metabolism*
Aryl Hydrocarbon Hydroxylases*
Base Sequence
Cytochrome P-450 CYP2C19
Cytochrome P-450 Enzyme System / genetics*
Cytochrome P-450 Enzyme System / metabolism*
DNA Primers / genetics
Genetic Techniques* / statistics & numerical data
Genotype
Humans
Mephenytoin / metabolism*
Mixed Function Oxygenases / genetics*
Mixed Function Oxygenases / metabolism*
Molecular Sequence Data
Mutation*
Phenotype
Polymerase Chain Reaction / methods
Polymerase Chain Reaction / statistics & numerical data
Polymorphism, Genetic*
Sensitivity and Specificity

Substances

Anticonvulsants
DNA Primers
Cytochrome P-450 Enzyme System
Mixed Function Oxygenases
Aryl Hydrocarbon Hydroxylases
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Mephenytoin